查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2041779

生殖毒性測試市場預測至2034年－按產品、方法、技術、最終用戶和地區分類的全球分析

Reproductive Toxicity Testing Market Forecasts to 2034 - Global Analysis By Product (Consumables, Assays and Equipment), Method (Cellular Assays, In-Silico Models, Biochemical Assays and Ex-Vivo Models), Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球生殖毒性測試市場規模將達到 163 億美元，並在預測期內以 11.4% 的複合年成長率成長，到 2034 年將達到 386 億美元。

生殖毒性試驗旨在評估各種物質對人類和動物生殖系統的潛在不良影響。評估生殖毒性的調查方法多種多樣，包括體內試驗（動物研究）、體外試驗、計算模型和高通量篩檢。這些評估涵蓋生育力、胚胎發育、致畸性、致突變性和荷爾蒙失調等終點指標，為風險評估和監管決策提供關鍵數據。

根據 ClinicalTrials.gov 的數據，截至 2020 年 8 月，該資料庫共包含 281,305 項註冊研究。

測試技術的進步

毒性測試領域正因高通量篩檢、先進的體外檢測和預測性計算模型等持續創新而改變。這些進步提高了測試的準確性、效率和成本效益，從而能夠全面評估生殖毒性，同時減少對動物測試的依賴。此外，高靈敏度和高特異性測試方法的開發將有助於更準確地預測人體對物質的反應，從而加快藥物研發和產品安全評估的決策速度。因此，這些技術在化學、製藥和消費品行業的應用將不斷增加，從而推動市場擴張。

成本和時間負擔

進行全面的生殖毒性測試，特別是長期評估和法規遵循測試，需要耗費大量資金和漫長的測試週期。資源和時間的投入可能造成沉重的負擔，尤其對於中小企業和研究機構而言，這可能會影響它們進行廣泛測試的能力。這種經濟負擔和漫長的測試週期會阻礙此類測試的廣泛應用，限制獲得全面的生殖毒性評估，並影響產品開發和監管核准流程的進度。

製藥和化學工業的擴張

隨著醫藥和化學產業的持續成長，新藥、化學品和消費品的研發日益增加。全面的生殖毒性測試對於確保這些產品上市前的安全性和合規性至關重要。對這類全面安全評估日益成長的需求，為測試服務供應商提供了提供可靠且高效測試服務的機會。此外，滿足不斷擴大的行業需求將促進生殖毒性測試市場的成長，並透過滿足醫藥和化學產品安全評估的需求，最終為消費者帶來更安全的產品。

監管障礙

不同地區監管標準的多樣性和嚴格程度給檢測實驗室和服務供應商帶來了挑戰。合規要求的差異使得建立統一的檢測方案變得困難，可能導致產品核准和市場准入延遲。應對這些不同的法規結構增加了複雜性，影響了生殖毒性檢測服務的效率和可近性。

新冠疫情的感染疾病

新冠肺炎疫情對生殖毒性檢測市場造成了負面影響，供應鏈中斷、實驗室關閉以及研究重點的轉移都加劇了這個問題。這些因素使得生殖毒性檢測變得更加困難和耗時。這種初期影響反映了疫情期間生物技術和製藥行業面臨的更廣泛挑戰。然而，隨著時間的推移，世界逐漸適應了疫情帶來的挑戰，該市場展現出了韌性並實現了持續成長。

在預測期內，細胞培養技術領域預計將成為規模最大的領域。

細胞培養技術預計將佔據最大的市場佔有率。細胞培養技術透過觀察細胞對化學物質和藥物的反應，能夠評估毒性、遺傳毒性和其他生殖終點。基於細胞培養的檢測方法為生殖毒性研究提供了寶貴的見解，從而支持藥物研發、安全性評估和法規遵循。此外，細胞培養技術的進步提高了準確性、效率和預測能力，塑造了生殖毒性測試和調查方法的發展趨勢，並顯著促進了該細分市場的成長。

在預測期內，製藥和生技公司板塊預計將呈現最高的複合年成長率。

預計在預測期內，製藥和生物技術公司板塊將強勁成長。這些公司廣泛利用生殖毒性測試來評估藥物對生殖健康的潛在不良影響。此類測試確保符合監管標準，提高藥品的安全性，並為藥物研發階段的決策提供基礎。此外，這些公司正在推動對全面、專業的生殖毒性測試服務的需求，在塑造市場格局的同時，也優先考慮其產品對全球消費者的安全性和有效性，發揮至關重要的作用。

市佔率最大的地區：

在預測期內，亞太地區佔據了最大的市場佔有率，這主要得益於其嚴格的法規結構、日益增強的生殖健康意識以及調查方法的技術進步。此外，不斷擴大的研究合作和對藥物安全評估的日益重視也進一步推動了市場需求。該地區不斷發展的製藥業，加上政府的支持性舉措，已使亞太地區成為生殖毒性檢測服務的中心，日益激烈的競爭和創新正在重塑其市場格局。

複合年成長率最高的地區：

由於北美地區擁有嚴格的法規結構，並日益重視藥物安全，預計該地區在預測期內將實現盈利成長。該地區強大的製藥和生物技術產業，尤其是在美國和加拿大，正在推動對生殖毒性檢測服務的需求。此外，研究機構與產業相關人員之間的合作正在促進調查方法的進步，使北美成為生殖毒性檢測服務和製藥領域創新的重要中心。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球生殖毒性測試市場：依產品分類

  • 消耗品
  • 偵測
    • 細菌毒性試驗
    • 細菌毒性試驗
    • 受體結合試驗
    • 基於細胞的ELISA和西方墨點法
    • 組織培養試驗
  • 裝置

第6章 全球生殖毒性測試市場：依方法分類

  • 細胞分析
  • In Silico模型
  • 生化分析
  • 體外模型

第7章 全球生殖毒性檢測市場：依技術分類

  • 細胞培養技術
  • 毒理基因組學
  • 高通量技術

第8章 全球生殖毒性測試市場：依最終用戶分類

  • 學術研究機構
  • 受託研究機構
  • 製藥和生物技術公司
  • 其他最終用戶

第9章 全球生殖毒性檢測市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第10章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章：公司簡介

  • Thermo Fisher Scientific
  • Laboratory Corporation of America Holdings
  • Charles River Laboratories International
  • Eurofins Scientific
  • Syngene International Limited
  • Jubilant Life Sciences Limited
  • Gentronix Ltd
  • Creative Bioarray
  • Inotiv Inc
  • MB Research Laboratories
  • Catalent, Inc.
  • Bio-Rad Laboratories
  • Evotec
  • QIAGEN
  • Promega Corporation
Product Code: SMRC24843

According to Stratistics MRC, the Global Reproductive Toxicity Testing Market is accounted for $16.3 billion in 2026 and is expected to reach $38.6 billion by 2034 growing at a CAGR of 11.4% during the forecast period. Reproductive toxicity testing involves assessing the potential adverse effects of various substances on the reproductive systems of humans or animals. Various testing methodologies, including in vivo (animal testing), in vitro assays, computational models, and high-throughput screening, are employed to assess reproductive toxicity. The assessments encompass evaluating endpoints such as fertility, embryonic development, teratogenicity, mutagenicity, and hormonal disruptions, providing essential data to guide risk assessment and regulatory decisions.

According to the ClinicalTrials.gov, a total of 281,305 studies are registered on their database as of August 2020.

Market Dynamics:

Driver:

Advancements in testing technologies

Ongoing innovations, such as high-throughput screening, sophisticated in vitro assays, and predictive computational models, revolutionise the field of toxicity testing. These advancements enhance testing accuracy, efficiency, and cost-effectiveness, allowing for comprehensive evaluation of reproductive toxicity with reduced reliance on animal testing. Furthermore, the development of more sensitive and specific testing methods enables better prediction of human responses to substances, expediting decision-making in drug development and product safety assessments. Consequently, the chemical, pharmaceutical, and consumer goods industries will employ it more frequently, driving market expansion.

Restraint:

Cost and time intensiveness

Conducting comprehensive reproductive toxicity studies involves substantial expenses and lengthy testing periods, especially for long-term assessments and regulatory compliance. The investment of resources and time can be prohibitive, particularly for smaller companies or research institutions, impacting their ability to conduct extensive testing. The financial burden and extended timelines hinder widespread adoption of these tests, potentially limiting access to comprehensive reproductive toxicity evaluations and affecting the pace of product development and regulatory approval processes.

Opportunity:

Expanding Pharmaceutical and Chemical Industries

With continuous growth in the pharmaceutical and chemical sectors, there's been an increased development of new drugs, chemicals, and consumer products. Ensuring the safety and regulatory compliance of these products before market entry necessitates comprehensive reproductive toxicity testing. This rising demand for thorough safety assessments presents an opportunity for testing service providers to offer reliable and efficient testing services. Moreover, addressing the needs of expanding industries fuels the growth of the reproductive toxicity testing market, catering to the demand for safety evaluations in pharmaceuticals and chemicals, thus ensuring safer products for consumers.

Threat:

Regulatory hurdles

Diverse and stringent regulatory standards across regions pose challenges for testing laboratories and service providers. Varying compliance demands complicate the establishment of uniform testing protocols, potentially delaying product approvals and market entry. Negotiating these diverse regulatory frameworks creates complexity, impacting the efficiency and accessibility of reproductive toxicity testing services.

Covid-19 Impact

The COVID-19 pandemic had a detrimental impact on the market for reproductive toxicity testing due to supply chain disruptions, laboratory closures, and a change in research priorities. These factors made reproductive toxicity testing more difficult and time-consuming to perform. This initial effect was a reflection of the larger difficulties that the biotechnology and pharmaceutical sectors experienced during the epidemic. However, the market demonstrated robustness and sustained expansion as time passed and the world adjusted to the pandemic's challenges.

The cell culture technology segment is expected to be the largest during the forecast period

The cell culture technology segment is estimated to hold the largest share. Cell culture technology allows for the evaluation of toxicity, genotoxicity, and other reproductive endpoints by observing cellular responses to chemical compounds or pharmaceuticals. Cell culture-based assays provide valuable insights into reproductive toxicity, aiding in drug development, safety assessment, and regulatory compliance. Moreover, advancements in cell culture techniques enhance accuracy, efficiency, and predictive capabilities, shaping the landscape of reproductive toxicity testing methodologies and contributing significantly to this market segment's growth.

The pharmaceutical and biotechnology companies segment is expected to have the highest CAGR during the forecast period

The pharmaceutical and biotechnology companies segment is anticipated to have lucrative growth during the forecast period. Pharmaceutical and biotechnology companies extensively utilise reproductive toxicity testing to assess potential adverse effects on reproductive health. Such testing ensures compliance with regulatory standards, enhances drug safety profiles, and aids in making informed decisions during drug development stages. Moreover, these companies drive the demand for comprehensive and specialised reproductive toxicity testing services, playing a critical role in shaping the market while prioritising the safety and efficacy of their products for global consumers.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to its stringent regulatory frameworks, rising awareness of reproductive health, and technological advancements in testing methodologies. Furthermore, growing research collaborations and a burgeoning focus on drug safety assessment further propel market demand. The region's evolving pharmaceutical industry, coupled with supportive government initiatives, positions the Asia-Pacific as a hub for reproductive toxicity testing services, with heightened competition and innovation shaping its landscape.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to stringent regulatory frameworks and a heightened focus on pharmaceutical safety. The region's robust pharmaceutical and biotechnology industries, particularly in the United States and Canada, drive the demand for reproductive toxicity testing services. Furthermore, collaborations between research institutions and industry players further contribute to advancements in testing methodologies, positioning North America as a pivotal hub for reproductive toxicity testing services and innovations in the pharmaceutical sector.

Key players in the market

Some of the key players in the Reproductive Toxicity Testing Market include Thermo Fisher Scientific, Laboratory Corporation of America Holdings, Charles River Laboratories International, Eurofins Scientific, Syngene International Limited, Jubilant Life Sciences Limited, Gentronix Ltd, Creative Bioarray, Inotiv Inc, MB Research Laboratories, Catalent, Inc., Bio-Rad Laboratories, Evotec, QIAGEN and Promega Corporation.

Key Developments:

In May 2023, Wheeler Bio, a CDMO, collaborated with Charles River Labs to utilize RightSource, a flexible biologic testing lab, at its Oklahoma City facility. This partnership aimed to enhance Wheeler Bio's quality control without the need to establish its own lab, ultimately benefiting its biologic products and potential clients.

In October 2022, Thermo Fisher Scientific Inc. declared that it had expanded its laboratory operations in Highland Heights, Kentucky, to assist customers in delivering personalized medications to patients. The existing facility, which included central laboratory and biomarker operations, provided biopharma customers with high-quality laboratory services to accelerate drug development. This move increased the company's clinical diagnostics business worldwide and enhanced its global presence across the business space.

Products Covered:

  • Consumables
  • Assays
  • Equipment

Methods Covered:

  • Cellular Assays
  • In-Silico Models
  • Biochemical Assays
  • Ex-Vivo Models

Technologies Covered:

  • Cell Culture Technology
  • Toxicogenomics
  • High-Throughput Technology

End Users Covered:

  • Academic and Research Institutes
  • Contract Research Organizations
  • Pharmaceutical and Biotechnology Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Reproductive Toxicity Testing Market, By Product

  • 5.1 Introduction
  • 5.2 Consumables
  • 5.3 Assays
    • 5.3.1 Bacterial Toxicity Assays
    • 5.3.2 Bacterial Toxicity Assays
    • 5.3.3 Receptor-Binding Assays
    • 5.3.4 Cell-Based ELISA & Western Blot
    • 5.3.5 Tissue Culture Assays
  • 5.4 Equipment

6 Global Reproductive Toxicity Testing Market, By Method

  • 6.1 Introduction
  • 6.2 Cellular Assays
  • 6.3 In-Silico Models
  • 6.4 Biochemical Assays
  • 6.5 Ex-Vivo Models

7 Global Reproductive Toxicity Testing Market, By Technology

  • 7.1 Introduction
  • 7.2 Cell Culture Technology
  • 7.3 Toxicogenomics
  • 7.4 High-Throughput Technology

8 Global Reproductive Toxicity Testing Market, By End User

  • 8.1 Introduction
  • 8.2 Academic and Research Institutes
  • 8.3 Contract Research Organizations
  • 8.4 Pharmaceutical and Biotechnology Companies
  • 8.5 Other End Users

9 Global Reproductive Toxicity Testing Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Thermo Fisher Scientific
  • 11.2 Laboratory Corporation of America Holdings
  • 11.3 Charles River Laboratories International
  • 11.4 Eurofins Scientific
  • 11.5 Syngene International Limited
  • 11.6 Jubilant Life Sciences Limited
  • 11.7 Gentronix Ltd
  • 11.8 Creative Bioarray
  • 11.9 Inotiv Inc
  • 11.10 MB Research Laboratories
  • 11.11 Catalent, Inc.
  • 11.12 Bio-Rad Laboratories
  • 11.13 Evotec
  • 11.14 QIAGEN
  • 11.15 Promega Corporation

List of Tables

  • Table 1 Global Reproductive Toxicity Testing Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Reproductive Toxicity Testing Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Reproductive Toxicity Testing Market Outlook, By Consumables (2023-2034) ($MN)
  • Table 4 Global Reproductive Toxicity Testing Market Outlook, By Assays (2023-2034) ($MN)
  • Table 5 Global Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2023-2034) ($MN)
  • Table 6 Global Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2023-2034) ($MN)
  • Table 7 Global Reproductive Toxicity Testing Market Outlook, By Receptor-Binding Assays (2023-2034) ($MN)
  • Table 8 Global Reproductive Toxicity Testing Market Outlook, By Cell-Based ELISA & Western Blot (2023-2034) ($MN)
  • Table 9 Global Reproductive Toxicity Testing Market Outlook, By Tissue Culture Assays (2023-2034) ($MN)
  • Table 10 Global Reproductive Toxicity Testing Market Outlook, By Equipment (2023-2034) ($MN)
  • Table 11 Global Reproductive Toxicity Testing Market Outlook, By Method (2023-2034) ($MN)
  • Table 12 Global Reproductive Toxicity Testing Market Outlook, By Cellular Assays (2023-2034) ($MN)
  • Table 13 Global Reproductive Toxicity Testing Market Outlook, By In-Silico Models (2023-2034) ($MN)
  • Table 14 Global Reproductive Toxicity Testing Market Outlook, By Biochemical Assays (2023-2034) ($MN)
  • Table 15 Global Reproductive Toxicity Testing Market Outlook, By Ex-Vivo Models (2023-2034) ($MN)
  • Table 16 Global Reproductive Toxicity Testing Market Outlook, By Technology (2023-2034) ($MN)
  • Table 17 Global Reproductive Toxicity Testing Market Outlook, By Cell Culture Technology (2023-2034) ($MN)
  • Table 18 Global Reproductive Toxicity Testing Market Outlook, By Toxicogenomics (2023-2034) ($MN)
  • Table 19 Global Reproductive Toxicity Testing Market Outlook, By High-Throughput Technology (2023-2034) ($MN)
  • Table 20 Global Reproductive Toxicity Testing Market Outlook, By End User (2023-2034) ($MN)
  • Table 21 Global Reproductive Toxicity Testing Market Outlook, By Academic and Research Institutes (2023-2034) ($MN)
  • Table 22 Global Reproductive Toxicity Testing Market Outlook, By Contract Research Organizations (2023-2034) ($MN)
  • Table 23 Global Reproductive Toxicity Testing Market Outlook, By Pharmaceutical and Biotechnology Companies (2023-2034) ($MN)
  • Table 24 Global Reproductive Toxicity Testing Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 25 North America Reproductive Toxicity Testing Market Outlook, By Country (2023-2034) ($MN)
  • Table 26 North America Reproductive Toxicity Testing Market Outlook, By Product (2023-2034) ($MN)
  • Table 27 North America Reproductive Toxicity Testing Market Outlook, By Consumables (2023-2034) ($MN)
  • Table 28 North America Reproductive Toxicity Testing Market Outlook, By Assays (2023-2034) ($MN)
  • Table 29 North America Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2023-2034) ($MN)
  • Table 30 North America Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2023-2034) ($MN)
  • Table 31 North America Reproductive Toxicity Testing Market Outlook, By Receptor-Binding Assays (2023-2034) ($MN)
  • Table 32 North America Reproductive Toxicity Testing Market Outlook, By Cell-Based ELISA & Western Blot (2023-2034) ($MN)
  • Table 33 North America Reproductive Toxicity Testing Market Outlook, By Tissue Culture Assays (2023-2034) ($MN)
  • Table 34 North America Reproductive Toxicity Testing Market Outlook, By Equipment (2023-2034) ($MN)
  • Table 35 North America Reproductive Toxicity Testing Market Outlook, By Method (2023-2034) ($MN)
  • Table 36 North America Reproductive Toxicity Testing Market Outlook, By Cellular Assays (2023-2034) ($MN)
  • Table 37 North America Reproductive Toxicity Testing Market Outlook, By In-Silico Models (2023-2034) ($MN)
  • Table 38 North America Reproductive Toxicity Testing Market Outlook, By Biochemical Assays (2023-2034) ($MN)
  • Table 39 North America Reproductive Toxicity Testing Market Outlook, By Ex-Vivo Models (2023-2034) ($MN)
  • Table 40 North America Reproductive Toxicity Testing Market Outlook, By Technology (2023-2034) ($MN)
  • Table 41 North America Reproductive Toxicity Testing Market Outlook, By Cell Culture Technology (2023-2034) ($MN)
  • Table 42 North America Reproductive Toxicity Testing Market Outlook, By Toxicogenomics (2023-2034) ($MN)
  • Table 43 North America Reproductive Toxicity Testing Market Outlook, By High-Throughput Technology (2023-2034) ($MN)
  • Table 44 North America Reproductive Toxicity Testing Market Outlook, By End User (2023-2034) ($MN)
  • Table 45 North America Reproductive Toxicity Testing Market Outlook, By Academic and Research Institutes (2023-2034) ($MN)
  • Table 46 North America Reproductive Toxicity Testing Market Outlook, By Contract Research Organizations (2023-2034) ($MN)
  • Table 47 North America Reproductive Toxicity Testing Market Outlook, By Pharmaceutical and Biotechnology Companies (2023-2034) ($MN)
  • Table 48 North America Reproductive Toxicity Testing Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 49 Europe Reproductive Toxicity Testing Market Outlook, By Country (2023-2034) ($MN)
  • Table 50 Europe Reproductive Toxicity Testing Market Outlook, By Product (2023-2034) ($MN)
  • Table 51 Europe Reproductive Toxicity Testing Market Outlook, By Consumables (2023-2034) ($MN)
  • Table 52 Europe Reproductive Toxicity Testing Market Outlook, By Assays (2023-2034) ($MN)
  • Table 53 Europe Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2023-2034) ($MN)
  • Table 54 Europe Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2023-2034) ($MN)
  • Table 55 Europe Reproductive Toxicity Testing Market Outlook, By Receptor-Binding Assays (2023-2034) ($MN)
  • Table 56 Europe Reproductive Toxicity Testing Market Outlook, By Cell-Based ELISA & Western Blot (2023-2034) ($MN)
  • Table 57 Europe Reproductive Toxicity Testing Market Outlook, By Tissue Culture Assays (2023-2034) ($MN)
  • Table 58 Europe Reproductive Toxicity Testing Market Outlook, By Equipment (2023-2034) ($MN)
  • Table 59 Europe Reproductive Toxicity Testing Market Outlook, By Method (2023-2034) ($MN)
  • Table 60 Europe Reproductive Toxicity Testing Market Outlook, By Cellular Assays (2023-2034) ($MN)
  • Table 61 Europe Reproductive Toxicity Testing Market Outlook, By In-Silico Models (2023-2034) ($MN)
  • Table 62 Europe Reproductive Toxicity Testing Market Outlook, By Biochemical Assays (2023-2034) ($MN)
  • Table 63 Europe Reproductive Toxicity Testing Market Outlook, By Ex-Vivo Models (2023-2034) ($MN)
  • Table 64 Europe Reproductive Toxicity Testing Market Outlook, By Technology (2023-2034) ($MN)
  • Table 65 Europe Reproductive Toxicity Testing Market Outlook, By Cell Culture Technology (2023-2034) ($MN)
  • Table 66 Europe Reproductive Toxicity Testing Market Outlook, By Toxicogenomics (2023-2034) ($MN)
  • Table 67 Europe Reproductive Toxicity Testing Market Outlook, By High-Throughput Technology (2023-2034) ($MN)
  • Table 68 Europe Reproductive Toxicity Testing Market Outlook, By End User (2023-2034) ($MN)
  • Table 69 Europe Reproductive Toxicity Testing Market Outlook, By Academic and Research Institutes (2023-2034) ($MN)
  • Table 70 Europe Reproductive Toxicity Testing Market Outlook, By Contract Research Organizations (2023-2034) ($MN)
  • Table 71 Europe Reproductive Toxicity Testing Market Outlook, By Pharmaceutical and Biotechnology Companies (2023-2034) ($MN)
  • Table 72 Europe Reproductive Toxicity Testing Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 73 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Country (2023-2034) ($MN)
  • Table 74 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Product (2023-2034) ($MN)
  • Table 75 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Consumables (2023-2034) ($MN)
  • Table 76 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Assays (2023-2034) ($MN)
  • Table 77 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2023-2034) ($MN)
  • Table 78 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2023-2034) ($MN)
  • Table 79 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Receptor-Binding Assays (2023-2034) ($MN)
  • Table 80 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Cell-Based ELISA & Western Blot (2023-2034) ($MN)
  • Table 81 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Tissue Culture Assays (2023-2034) ($MN)
  • Table 82 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Equipment (2023-2034) ($MN)
  • Table 83 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Method (2023-2034) ($MN)
  • Table 84 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Cellular Assays (2023-2034) ($MN)
  • Table 85 Asia Pacific Reproductive Toxicity Testing Market Outlook, By In-Silico Models (2023-2034) ($MN)
  • Table 86 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Biochemical Assays (2023-2034) ($MN)
  • Table 87 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Ex-Vivo Models (2023-2034) ($MN)
  • Table 88 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Technology (2023-2034) ($MN)
  • Table 89 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Cell Culture Technology (2023-2034) ($MN)
  • Table 90 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Toxicogenomics (2023-2034) ($MN)
  • Table 91 Asia Pacific Reproductive Toxicity Testing Market Outlook, By High-Throughput Technology (2023-2034) ($MN)
  • Table 92 Asia Pacific Reproductive Toxicity Testing Market Outlook, By End User (2023-2034) ($MN)
  • Table 93 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Academic and Research Institutes (2023-2034) ($MN)
  • Table 94 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Contract Research Organizations (2023-2034) ($MN)
  • Table 95 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Pharmaceutical and Biotechnology Companies (2023-2034) ($MN)
  • Table 96 Asia Pacific Reproductive Toxicity Testing Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 97 South America Reproductive Toxicity Testing Market Outlook, By Country (2023-2034) ($MN)
  • Table 98 South America Reproductive Toxicity Testing Market Outlook, By Product (2023-2034) ($MN)
  • Table 99 South America Reproductive Toxicity Testing Market Outlook, By Consumables (2023-2034) ($MN)
  • Table 100 South America Reproductive Toxicity Testing Market Outlook, By Assays (2023-2034) ($MN)
  • Table 101 South America Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2023-2034) ($MN)
  • Table 102 South America Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2023-2034) ($MN)
  • Table 103 South America Reproductive Toxicity Testing Market Outlook, By Receptor-Binding Assays (2023-2034) ($MN)
  • Table 104 South America Reproductive Toxicity Testing Market Outlook, By Cell-Based ELISA & Western Blot (2023-2034) ($MN)
  • Table 105 South America Reproductive Toxicity Testing Market Outlook, By Tissue Culture Assays (2023-2034) ($MN)
  • Table 106 South America Reproductive Toxicity Testing Market Outlook, By Equipment (2023-2034) ($MN)
  • Table 107 South America Reproductive Toxicity Testing Market Outlook, By Method (2023-2034) ($MN)
  • Table 108 South America Reproductive Toxicity Testing Market Outlook, By Cellular Assays (2023-2034) ($MN)
  • Table 109 South America Reproductive Toxicity Testing Market Outlook, By In-Silico Models (2023-2034) ($MN)
  • Table 110 South America Reproductive Toxicity Testing Market Outlook, By Biochemical Assays (2023-2034) ($MN)
  • Table 111 South America Reproductive Toxicity Testing Market Outlook, By Ex-Vivo Models (2023-2034) ($MN)
  • Table 112 South America Reproductive Toxicity Testing Market Outlook, By Technology (2023-2034) ($MN)
  • Table 113 South America Reproductive Toxicity Testing Market Outlook, By Cell Culture Technology (2023-2034) ($MN)
  • Table 114 South America Reproductive Toxicity Testing Market Outlook, By Toxicogenomics (2023-2034) ($MN)
  • Table 115 South America Reproductive Toxicity Testing Market Outlook, By High-Throughput Technology (2023-2034) ($MN)
  • Table 116 South America Reproductive Toxicity Testing Market Outlook, By End User (2023-2034) ($MN)
  • Table 117 South America Reproductive Toxicity Testing Market Outlook, By Academic and Research Institutes (2023-2034) ($MN)
  • Table 118 South America Reproductive Toxicity Testing Market Outlook, By Contract Research Organizations (2023-2034) ($MN)
  • Table 119 South America Reproductive Toxicity Testing Market Outlook, By Pharmaceutical and Biotechnology Companies (2023-2034) ($MN)
  • Table 120 South America Reproductive Toxicity Testing Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 121 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Country (2023-2034) ($MN)
  • Table 122 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Product (2023-2034) ($MN)
  • Table 123 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Consumables (2023-2034) ($MN)
  • Table 124 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Assays (2023-2034) ($MN)
  • Table 125 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2023-2034) ($MN)
  • Table 126 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Bacterial Toxicity Assays (2023-2034) ($MN)
  • Table 127 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Receptor-Binding Assays (2023-2034) ($MN)
  • Table 128 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Cell-Based ELISA & Western Blot (2023-2034) ($MN)
  • Table 129 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Tissue Culture Assays (2023-2034) ($MN)
  • Table 130 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Equipment (2023-2034) ($MN)
  • Table 131 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Method (2023-2034) ($MN)
  • Table 132 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Cellular Assays (2023-2034) ($MN)
  • Table 133 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By In-Silico Models (2023-2034) ($MN)
  • Table 134 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Biochemical Assays (2023-2034) ($MN)
  • Table 135 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Ex-Vivo Models (2023-2034) ($MN)
  • Table 136 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Technology (2023-2034) ($MN)
  • Table 137 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Cell Culture Technology (2023-2034) ($MN)
  • Table 138 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Toxicogenomics (2023-2034) ($MN)
  • Table 139 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By High-Throughput Technology (2023-2034) ($MN)
  • Table 140 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By End User (2023-2034) ($MN)
  • Table 141 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Academic and Research Institutes (2023-2034) ($MN)
  • Table 142 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Contract Research Organizations (2023-2034) ($MN)
  • Table 143 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Pharmaceutical and Biotechnology Companies (2023-2034) ($MN)
  • Table 144 Middle East & Africa Reproductive Toxicity Testing Market Outlook, By Other End Users (2023-2034) ($MN)